Greenphire joins clinical trial alliance
Finance lifecycle management firm Greenphire has joined the Decentralized Trials & Research Alliance, a group of 100 life science and healthcare organizations. Read More
VenBio raises $550 million in venture capital
Life science venture capital firm VenBio announced it closed its fourth life sciences venture capital fund on approximately $550 million in capital commitments. Read More
Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of its messenger RNA COVID-19 vaccine in individuals ages 18 years and older. Read More
Resolve Biosciences announces Molecular Cartography service
Resolve Biosciences has announced the launch of its Molecular Cartography service to provide research scientists with high-resolution views of subcellular gene expression. Read More
Agilent launches new exome design for genomics research
Agilent Technologies has released a new exome design that provides content for genomics research. Read More
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine. Read More
Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines. Read More
Bruker expands timsTOF product line
Bruker has added two new instruments to its trapped ion mobility spectrometry time-of-flight (timsTOF) product suite, including the second-generation of its timsTOF Pro system for 4D proteomics. Read More
Samsung Biologics readies mRNA vaccine drug substance production
Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities. Read More
Sanofi, GSK initiate phase III trial of COVID-19 vaccine
Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine candidate. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
